RxDoctor Payments Data

Alexander Hawkins, MD

Nephrology · Portland, ORNPI 1770016198

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.9% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $247, more than ten times the $12 reported in 2022.

$387in general payments, 2019–2025

Across 21 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$72
  • AstraZeneca$69
  • Mallinckrodt Hospital Products Inc.$32
  • Calliditas Therapeutics US Inc.$30
  • Scpharmaceuticals Inc.$26
  • Amgen$26
  • plus $133 from 7 others

What the payments were for

  • Food & beverage$37597%
  • Education$123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$387 in reported general payments places this provider in the 60th percentile of 120 nephrology providers in Oregon.

See all nephrology providers in Oregon

Medicare billing

Part B allowed, 2024
$128,722
Medicare patients
356
Services billed
1,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin24$26,035
FarxigaDapagliflozin Propanediol16$25,833
Lanthanum Carbonate11$10,029
Cinacalcet Hcl13$7,576
Potassium Chloride57$3,530
Sevelamer Carbonate46$3,133
Torsemide96$2,786
Calcium Acetate44$2,643
Eplerenone23$1,734
Calcitriol34$1,309
Losartan Potassium90$1,139
Nifedipine ErNifedipine60$1,047
Midodrine Hcl12$695
Carvedilol64$650
Chlorthalidone37$628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$23$26,03524 claims
AstraZenecaFarxiga$69$25,83316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 120 nephrology providers in Oregon.

Other nephrology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →